Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Amazon Explores AI Content Marketplace With Media Publishers 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2018 -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that on February 20, 2018, the compensation committee of the Company's board of directors granted six new employees the option to purchase an aggregate of 20,670 shares of the Company's common stock and 10,360 restricted stock units. Each stock option has an exercise price per share equal to $10.75, which was the closing trading price on February 20, 2018. The stock options and restricted stock units were granted pursuant to the Company's 2014 Employment Commencement Incentive Plan, as amended, which was approved by the Company's board of directors in December 2014 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
About Achaogen
Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments for MDR gram-negative infections. Achaogen is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. The Food and Drug Administration has granted plazomicin Breakthrough Therapy designation for the treatment of bloodstream infections caused by certain Enterobacteriaceae in patients who have limited or no alternative treatment options. The Company's second product candidate is C-Scape, an orally-administered beta-lactam/beta-lactamase inhibitor combination. Achaogen's plazomicin program has been funded, and its C-Scape program is funded, in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA). Achaogen has other programs in early and late preclinical stages of development focused on other MDR gram-negative infections and additional disease areas. All product candidates, including plazomicin, are investigational only and have not been approved for commercialization. For more information, please visit www.achaogen.com.
Source: Achaogen, Inc. (NASDAQ:AKAO)
Investor Contact:
Ashley R. Robinson
LifeSci Partners, LLC
[email protected]
Media Contact:
Denise T. Powell
Red House Consulting, LLC
[email protected]
